UNSPSC 51372126: Nicomorphine hydrochloride

This classification denotes a morphine derivative and nicotinic acid C29H25N3O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7A91YL2XT2, chemically known as morphinan-3,6.alpha.-diol, 7,8-didehydro-4,5.alpha.-epoxy-17-methyl-, dinicotinate (ester), hydrochloride, but more generally known as nicomorphine hydrochloride, which bears US NIH Compound Identifier 166031. European Medicines Agency schedules Nicomorphine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22390.

Most nations, for tariff and trade purposes, schedule nicomorphine hydrochloride under HS 29391100 and SITC 54141. As of Q4 2014, NICOMORPHINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)OC(=O)C6CCCNC6)OC(=O)C7CCCNC7.CL.

UNSPSC 51372126 Nicomorphine hydrochloride is a Commodity code that captures opioid pharmaceutical products procured by state and local health systems, public health agencies, and cooperative purchasing alliances. However, the recent state and local opportunities tagged to this code show minimal direct activity in nicomorphine itself; instead, they reflect broader pharmaceutical procurement addressing naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves establishing supply agreements for pharmaceutical products through authorized wholesalers, managing quarterly deliveries to public health facilities, and negotiating pricing models that balance cost management with product availability and compliance with federal manufacturing and supply-chain security standards.

Solicitation activity appears concentrated in the South and Upper Midwest, with recent RFPs and RFQs posted from Florida, Texas, and Minnesota–Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer prescription capabilities outside traditional pharmacy benefit manager and wholesaler arrangements. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026. Vendors in these procurements must hold compliance certifications including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain adequate insurance coverage, and meet E-Verify requirements where applicable.